Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPID | Q08752 | 3/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.32 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6531479 | 0.94 | PPID (0.37) | PPIDDHODHEPHX2VSIRSYK | |
| SCHEMBL6531486 | 0.94 | PPID (0.37) | PPIDDHODHEPHX2VSIRSYK | |
| SCHEMBL6473173 | 0.85 | PRMT6 (0.41) | PPIDDHODHEPHX2MAPK1NR1H4 | |
| SCHEMBL6184965 | 0.83 | CTSB (0.38) | VSIRCTSBCTSSCTSKMEN1 | |
| SCHEMBL6184968 | 0.83 | CTSB (0.38) | VSIRCTSBCTSSCTSKMEN1 | |
| SCHEMBL6473169 | 0.78 | PRMT6 (0.42) | PPIDDHODHEPHX2NR1H4SYK | |
| SCHEMBL6473177 | 0.78 | PRMT6 (0.42) | PPIDDHODHEPHX2NR1H4SYK | |
| SCHEMBL4209244 | 0.78 | EPHX2 (0.36) | PPIDEPHX2VSIR | |
| SCHEMBL6473073 | 0.77 | EPHX2 (0.38) | PPIDEPHX2 | |
| SCHEMBL6473082 | 0.77 | EPHX2 (0.38) | PPIDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | PPID 2196/4885DHODH 2385/4885EPHX2 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.